Advus Financial Partners, LLC’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.14M Buy
4,517
+203
+5% +$43.7K 0.26% 80
2026
Q1
$938K Sell
4,314
-119
-3% -$26.4K 0.23% 79
2025
Q4
$1.01M Sell
4,433
-470
-10% -$107K 0.25% 68
2025
Q3
$1.14M Sell
4,903
-77
-2% -$15.7K 0.27% 63
2025
Q2
$924K Sell
4,980
-300
-6% -$55.8K 0.24% 71
2025
Q1
$1.11M Buy
5,280
+481
+10% +$93.5K 0.31% 53
2024
Q4
$853K Buy
4,799
+123
+3% +$22.6K 0.24% 61
2024
Q3
$923K Sell
4,676
-261
-5% -$48.7K 0.26% 56
2024
Q2
$847K Buy
4,937
+819
+20% +$136K 0.26% 59
2024
Q1
$750K Buy
4,118
+18
+0.4% +$3.1K 0.23% 62
2023
Q4
$635K Buy
4,100
+109
+3% +$15.9K 0.22% 66
2023
Q3
$595K Sell
3,991
-98
-2% -$14.4K 0.23% 64
2023
Q2
$551K Buy
4,089
+386
+10% +$56.6K 0.21% 68
2023
Q1
$590K Buy
3,703
+243
+7% +$37.2K 0.24% 60
2022
Q4
$559K Buy
3,460
+343
+11% +$52.6K 0.24% 59
2022
Q3
$418K Buy
3,117
+200
+7% +$28.7K 0.22% 69
2022
Q2
$447K Sell
2,917
-182
-6% -$27.8K 0.24% 62
2022
Q1
$502K Buy
+3,099
New +$450K 0.26% 60
2021
Q3
$365K Buy
+2,695
New +$308K 0.2% 60

Other funds holding ABBV

Advus Financial Partners, LLC's ABBV Position: Q2 2026 in Review

Advus Financial Partners, LLC increased its AbbVie (ABBV) stake by 4.7% in Q2 2026, buying an estimated $43.7K and bringing the position to 4,517 shares worth $1.14M. The position accounts for 0.26% of the portfolio, ranked #80.

Advus Financial Partners, LLC first reported a position in ABBV in Q3 2021 and has held it in 19 quarters since. 4,207 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Advus Financial Partners, LLC held 4,517 shares of AbbVie worth $1.14M as of Q2 2026.
  • Advus Financial Partners, LLC bought 203 AbbVie shares in Q2 2026, an estimated $43.7K.
  • AbbVie made up 0.26% of Advus Financial Partners, LLC's portfolio in Q2 2026, its #80 holding.
  • Advus Financial Partners, LLC first reported a position in AbbVie in Q3 2021 and has held it in 19 quarters since.
  • 4,207 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Advus Financial Partners, LLC's 13F filing for Q2 2026, filed 25 Aug 2026.